Open AccessBiomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Author(s) -
A. Bardia,
S.M. Tolaney,
K. Punie,
D. Loirat,
M. Oliveira,
K. Kalinsky,
A. Zelnak,
P. Aftimos,
F. Dalenc,
S. Sardesai,
E. Hamilton,
P. Sharma,
S. Recalde,
E.C. Gil,
T. Traina,
J. Oapos;Shaughnessy,
J. Cortes,
MF Tsai,
L. Vahdat,
V. Diéras,
L.A. Carey,
H.S. Rugo,
D.M. Goldenberg,
Q. Hong,
M. Olivo,
L.M. Itri,
S.A. Hurvitz
Publication year - 2021
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/q5ky-rc83
Subject(s) - triple negative breast cancer , biomarker , triple negative , breast cancer , oncology , cancer , medicine , chemotherapy , metastatic breast cancer , biology , biochemistry